• Home
  • Portfolio
  • Our Model
  • About
  • Insights
  • Contact
Life Sciences Start-up Governance: Who Decides What in a Dutch BV?

Life Sciences Start-up Governance: Who Decides What in a Dutch BV?

by Ivo De Nooijer | Oct 22, 2026 | Blog, Uncategorized

Strong science does not organise a company. Once a research project becomes a start-up, decisions about money, people, intellectual property and patient access need a clear home. This is the practical role of life sciences start-up governance. That sounds obvious. In...

Recent Posts

  • Life Sciences Start-up Governance: Who Decides What in a Dutch BV?
  • EMA’s PRIME scheme: what it means for drug development
  • Webinar: How do you design a clinical study that is registration-ready?
  • Funding socially responsible drug development
  • How does a public-private-partnerships in drug development work?

Recent Comments

  1. Living With PXE: What Patients Face and What Orfenix Is Doing About It | PXE Europe on Understanding pseudoxanthoma elasticum: Insights from Orfenix
  2. Interview "Impact PXE on daily life" - PXE on Understanding pseudoxanthoma elasticum: Insights from Orfenix

Contact us

J.H. Oortweg 21
2333CH Leiden
The Netherlands

info@orfenix.com

 

Orfenix repurposes existing compounds to create sustainable and affordable therapies, focusing on accessible healthcare through innovative and collaborative efforts.

Do you want to collaborate? Let us know on investors@orfenix.com

 

  • Follow